董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kathleen Tregoning | 女 | Director | 55 | 6.46万美元 | 未持股 | 2026-01-30 |
| Milind Deshpande | 男 | Director | 70 | 10.96万美元 | 未持股 | 2026-01-30 |
| John C. Pottage, Jr. | 男 | Director | 73 | 7.46万美元 | 未持股 | 2026-01-30 |
| Scott Jackson | 男 | Director | 61 | 7.21万美元 | 未持股 | 2026-01-30 |
| Esther Rajavelu | 女 | Director, Interim President and Chief Executive Officer, Chief Financial Officer, Chief Business Officer and Treasurer | 46 | 未披露 | 未持股 | 2026-01-30 |
| Frank E. Thomas | 男 | Chairman | 56 | 8.21万美元 | 未持股 | 2026-01-30 |
| Patrick Vink | 男 | Director | 63 | 8.46万美元 | 未持股 | 2026-01-30 |
| Cynthia Smith | 女 | Director | 57 | 6.46万美元 | 未持股 | 2026-01-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Timothy Keutzer | 男 | Chief Operating Officer | 58 | 未披露 | 未持股 | 2026-01-30 |
| Esther Rajavelu | 女 | Director, Interim President and Chief Executive Officer, Chief Financial Officer, Chief Business Officer and Treasurer | 46 | 未披露 | 未持股 | 2026-01-30 |
董事简历
中英对照 | 中文 | 英文- Kathleen Tregoning
-
Kathleen Tregoning获得了斯坦福大学国际关系学士学位和the Kennedy School of Government at Harvard University的公共政策硕士学位。凯思琳在政策发展和宣传、利益相关者拓展和外部参与方面有20多年的经验。她于1993在旧金山开始她的职业生涯，后来在洛杉矶担任安徒生顾问，后来担任了政策顾问，然后任市长助理副市长在凯思琳市任职。2001，凯思琳移居D.C。华盛顿，担任美国国会的一名专业工作人员。为众议院的主席工作，途径和手段委员会，众议院能源和商业委员会，参议院预算委员会。在这些职位上，她是国会议员在医疗保险、医疗补助、处方药、疾病管理、医疗信息技术和急性后护理等广泛保健问题上的关键资源。凯瑟琳2006年加入Biogen，担任公共政策和政府事务副主席。在九年的时间里，她建立了公司第一个全球政府事务小组，以推进政策，使创新生物制药产品能够交付给患者。2015年，Kathleen被任命为Biogen公司事务高级副总裁，负责全球范围内公司政策和宣传工作、公司与员工沟通、媒体关系、产品传播和慈善/社区外展等工作。2017年2月，她被任命为现任职位。
Kathleen Tregoning,served as Executive Vice President for External Affairs at Sanofi S.A. ("Sanofi"), a French multinational pharmaceutical company, where she was responsible for leading an integrated organization that brought together market access, communications, public policy, government affairs, patient advocacy and corporate social responsibility. Prior to joining Sanofi, Ms. Tregoning spent more than a decade at Biogen Inc., a multinational biotechnology company, first as Vice President, Public Policy & Government Affairs, from 2006 to 2015, and then as Senior Vice President, Corporate Affairs, from December 2015 to February 2017. Previously, Ms. Tregoning served as a professional staff member in the United States Congress, where she held health policy roles with the Senate Budget Committee, the House Energy & Commerce Committee, and the House Ways & Means Committee. Ms. Tregoning began her career with Andersen Consulting, where she developed business strategies and processes for clients in a range of industries, and later served as an Assistant Deputy Mayor for Policy & Budget in the office of the Mayor of Los Angeles. Ms. Tregoning graduated from Stanford University with a B.A. in International Relations and holds an M.A. in Public Policy from the Kennedy School of Government at Harvard University. - Kathleen Tregoning获得了斯坦福大学国际关系学士学位和the Kennedy School of Government at Harvard University的公共政策硕士学位。凯思琳在政策发展和宣传、利益相关者拓展和外部参与方面有20多年的经验。她于1993在旧金山开始她的职业生涯，后来在洛杉矶担任安徒生顾问，后来担任了政策顾问，然后任市长助理副市长在凯思琳市任职。2001，凯思琳移居D.C。华盛顿，担任美国国会的一名专业工作人员。为众议院的主席工作，途径和手段委员会，众议院能源和商业委员会，参议院预算委员会。在这些职位上，她是国会议员在医疗保险、医疗补助、处方药、疾病管理、医疗信息技术和急性后护理等广泛保健问题上的关键资源。凯瑟琳2006年加入Biogen，担任公共政策和政府事务副主席。在九年的时间里，她建立了公司第一个全球政府事务小组，以推进政策，使创新生物制药产品能够交付给患者。2015年，Kathleen被任命为Biogen公司事务高级副总裁，负责全球范围内公司政策和宣传工作、公司与员工沟通、媒体关系、产品传播和慈善/社区外展等工作。2017年2月，她被任命为现任职位。
- Kathleen Tregoning,served as Executive Vice President for External Affairs at Sanofi S.A. ("Sanofi"), a French multinational pharmaceutical company, where she was responsible for leading an integrated organization that brought together market access, communications, public policy, government affairs, patient advocacy and corporate social responsibility. Prior to joining Sanofi, Ms. Tregoning spent more than a decade at Biogen Inc., a multinational biotechnology company, first as Vice President, Public Policy & Government Affairs, from 2006 to 2015, and then as Senior Vice President, Corporate Affairs, from December 2015 to February 2017. Previously, Ms. Tregoning served as a professional staff member in the United States Congress, where she held health policy roles with the Senate Budget Committee, the House Energy & Commerce Committee, and the House Ways & Means Committee. Ms. Tregoning began her career with Andersen Consulting, where she developed business strategies and processes for clients in a range of industries, and later served as an Assistant Deputy Mayor for Policy & Budget in the office of the Mayor of Los Angeles. Ms. Tregoning graduated from Stanford University with a B.A. in International Relations and holds an M.A. in Public Policy from the Kennedy School of Government at Harvard University.
- Milind Deshpande
-
Milind Deshpande自2014年1月以来一直担任我们的董事会成员，目前担任董事会主席。Deshpande博士自2019年2月起担任Nayan Therapeutics的总裁兼首席执行官，自2020年1月起担任Avilar Therapeutics的总裁兼首席执行官。他也是RA Capital的风险合伙人，自2018年10月以来一直在该公司任职。Deshpande博士于2001年9月加入AchillionPharmaceuticals，Inc.，担任化学Vice President。2002年4月被任命为药物发现主管，2002年12月被任命为药物发现高级副总裁，2004年12月被任命为高级副总裁兼首席科学官，2007年6月被任命为研究执行Vice President兼首席科学官。他于2010年10月被提升为研究与开发总裁。2013年5月，Deshpande博士被任命为Achillion的总裁兼首席执行官，并加入其董事会，一直任职到2018年5月。加入Achillion公司之前，他曾担任Bristol-Myers Squibb Co.的制药研究所的铅发现和早期发现化学副董事（从1991年到2001年），在那里他曾管理新的临床候选药物的识别，以治疗传染病和神经系统疾病。从1988年到1991年，他曾担任Boston University Medical School的教员职务。Deshpande博士在印度接受本科教育后，在俄亥俄大学（Ohio University）获得有机化学博士学位。
Milind Deshpande,served as the President and Chief Executive Officer at Nayan Therapeutics from February 2019 to February 2022. Prior to his tenure at Nayan Therapeutics, Dr. Deshpande served as President and Chief Executive Officer of Avilar Therapeutics from January 2020 to June 2021. Additionally, Dr. Deshpande served as President and Chief Executive Officer, and as a member of the board of directors of Achillion Pharmaceuticals, Inc. ("Achillion") from May 2013 until May 2018. He joined Achillion in September 2001 as Vice President of Chemistry, was named Head of Drug Discovery in April 2002, Senior Vice President of Drug Discovery in December 2002, Senior Vice President and Chief Scientific Officer in December 2004, Executive Vice President of Research and Chief Scientific Officer in June 2007 and President of Research and Development in October 2010. Prior to joining Achillion, from 1991 to 2001, Dr. Deshpande was Associate Director of Lead Discovery and Early Discovery Chemistry at the Pharmaceutical Research Institute at Bristol-Myers Squibb Co., where he managed the identification of new clinical candidates to treat infectious and neurological diseases. From 1988 to 1991, he held a faculty position at Boston University Medical School. Dr. Deshpande received his Ph.D. in Organic Chemistry from Ohio University, following his undergraduate education in India. - Milind Deshpande自2014年1月以来一直担任我们的董事会成员，目前担任董事会主席。Deshpande博士自2019年2月起担任Nayan Therapeutics的总裁兼首席执行官，自2020年1月起担任Avilar Therapeutics的总裁兼首席执行官。他也是RA Capital的风险合伙人，自2018年10月以来一直在该公司任职。Deshpande博士于2001年9月加入AchillionPharmaceuticals，Inc.，担任化学Vice President。2002年4月被任命为药物发现主管，2002年12月被任命为药物发现高级副总裁，2004年12月被任命为高级副总裁兼首席科学官，2007年6月被任命为研究执行Vice President兼首席科学官。他于2010年10月被提升为研究与开发总裁。2013年5月，Deshpande博士被任命为Achillion的总裁兼首席执行官，并加入其董事会，一直任职到2018年5月。加入Achillion公司之前，他曾担任Bristol-Myers Squibb Co.的制药研究所的铅发现和早期发现化学副董事（从1991年到2001年），在那里他曾管理新的临床候选药物的识别，以治疗传染病和神经系统疾病。从1988年到1991年，他曾担任Boston University Medical School的教员职务。Deshpande博士在印度接受本科教育后，在俄亥俄大学（Ohio University）获得有机化学博士学位。
- Milind Deshpande,served as the President and Chief Executive Officer at Nayan Therapeutics from February 2019 to February 2022. Prior to his tenure at Nayan Therapeutics, Dr. Deshpande served as President and Chief Executive Officer of Avilar Therapeutics from January 2020 to June 2021. Additionally, Dr. Deshpande served as President and Chief Executive Officer, and as a member of the board of directors of Achillion Pharmaceuticals, Inc. ("Achillion") from May 2013 until May 2018. He joined Achillion in September 2001 as Vice President of Chemistry, was named Head of Drug Discovery in April 2002, Senior Vice President of Drug Discovery in December 2002, Senior Vice President and Chief Scientific Officer in December 2004, Executive Vice President of Research and Chief Scientific Officer in June 2007 and President of Research and Development in October 2010. Prior to joining Achillion, from 1991 to 2001, Dr. Deshpande was Associate Director of Lead Discovery and Early Discovery Chemistry at the Pharmaceutical Research Institute at Bristol-Myers Squibb Co., where he managed the identification of new clinical candidates to treat infectious and neurological diseases. From 1988 to 1991, he held a faculty position at Boston University Medical School. Dr. Deshpande received his Ph.D. in Organic Chemistry from Ohio University, following his undergraduate education in India.
- John C. Pottage, Jr.
-
JohnC.Pottage，Jr.自2018年9月以来一直担任我们的董事会成员。Pottage博士于2009年11月至2019年10月担任ViiV梦百合的高级副总裁兼首席科学和医疗官。Pottage博士从2008年9月到2009年11月担任高级副总裁，传染病医学发展中心主任，从2007年6月到2008年9月担任葛兰素史克全球抗病毒药物临床开发Vice President。在加入葛兰素史克之前，Pottage博士从2002年5月到2007年5月担任Achillion Pharmaceuticals的首席医疗官兼药物开发高级副总裁。Pottage从1998年7月到2002年5月担任Vertex Pharmaceuticals医疗主管。
John C. Pottage, Jr.,served as Senior Vice President and Chief Scientific and Medical Officer of ViiV Healthcare from November 2009 to October 2019. From September 2008 to November 2009, Dr. Pottage served as Senior Vice President, Head of Infectious Disease Medicine Development Center at GlaxoSmithKline and, from June 2007 to September 2008, he served as Vice President, Global Clinical Development of Antivirals also at GlaxoSmithKline. Prior to joining GlaxoSmithKline, from May 2002 to May 2007, Dr. Pottage served as Chief Medical Officer and Senior Vice President of Drug Development of Achillion. From July 1998 to May 2002, Dr. Pottage served as Medical Director of Vertex Pharmaceuticals Inc. Dr. Pottage served on the board of directors of Pardes Biosciences, Inc. from September 2022 to August 2023. - JohnC.Pottage，Jr.自2018年9月以来一直担任我们的董事会成员。Pottage博士于2009年11月至2019年10月担任ViiV梦百合的高级副总裁兼首席科学和医疗官。Pottage博士从2008年9月到2009年11月担任高级副总裁，传染病医学发展中心主任，从2007年6月到2008年9月担任葛兰素史克全球抗病毒药物临床开发Vice President。在加入葛兰素史克之前，Pottage博士从2002年5月到2007年5月担任Achillion Pharmaceuticals的首席医疗官兼药物开发高级副总裁。Pottage从1998年7月到2002年5月担任Vertex Pharmaceuticals医疗主管。
- John C. Pottage, Jr.,served as Senior Vice President and Chief Scientific and Medical Officer of ViiV Healthcare from November 2009 to October 2019. From September 2008 to November 2009, Dr. Pottage served as Senior Vice President, Head of Infectious Disease Medicine Development Center at GlaxoSmithKline and, from June 2007 to September 2008, he served as Vice President, Global Clinical Development of Antivirals also at GlaxoSmithKline. Prior to joining GlaxoSmithKline, from May 2002 to May 2007, Dr. Pottage served as Chief Medical Officer and Senior Vice President of Drug Development of Achillion. From July 1998 to May 2002, Dr. Pottage served as Medical Director of Vertex Pharmaceuticals Inc. Dr. Pottage served on the board of directors of Pardes Biosciences, Inc. from September 2022 to August 2023.
- Scott Jackson
-
Scott Jackson自2020年4月起担任我们的董事会成员。杰克逊先生曾于2008年4月至2016年7月担任CelatorPharmaceuticals，Inc.首席执行官兼董事会成员，当时该公司被Jazz Pharmaceuticals plc收购。杰克逊先生在制药和生物技术行业有着30多年的企业领导经验，在礼来公司、SmithKline Beecham PLC、Imclone Systems Incorporated、Centocor Inc.（强生公司的一个部门）担任销售、营销和商业开发方面的责任越来越大，Eximias制药公司和YM BiosciencesInc.杰克逊先生目前在Macrogenics，Inc.和Glycomimetics，Inc.的董事会任职。Jackson先生拥有费城药学院（Philadelphia College of Pharmacy and Science）的药学学士学位和圣母大学（University of Notre Dame）的工商管理硕士学位。
Scott Jackson,has more than thirty years of corporate leadership experience in the pharmaceutical and biotechnology industry and has held positions of increasing responsibility in sales, marketing and commercial development at Eli Lilly & Company, SmithKline Beecham plc, ImClone Systems Incorporated, Centocor Inc., a division of Johnson & Johnson, Eximias Pharmaceutical Corporation and YM BioSciences Inc. Mr. Jackson presently serves as chairman of the board of Mural Oncology plc, serves on the board of MacroGenics, Inc. and served on the board of GlycoMimetics, Inc. until February 2025. Mr. Jackson also serves on the board of directors at Philabundance, a non-profit organization that addresses food insecurity in the Philadelphia area. Mr. Jackson holds a B.S. in pharmacy from the Philadelphia College of Pharmacy and Science and an M.B.A. from the University of Notre Dame. - Scott Jackson自2020年4月起担任我们的董事会成员。杰克逊先生曾于2008年4月至2016年7月担任CelatorPharmaceuticals，Inc.首席执行官兼董事会成员，当时该公司被Jazz Pharmaceuticals plc收购。杰克逊先生在制药和生物技术行业有着30多年的企业领导经验，在礼来公司、SmithKline Beecham PLC、Imclone Systems Incorporated、Centocor Inc.（强生公司的一个部门）担任销售、营销和商业开发方面的责任越来越大，Eximias制药公司和YM BiosciencesInc.杰克逊先生目前在Macrogenics，Inc.和Glycomimetics，Inc.的董事会任职。Jackson先生拥有费城药学院（Philadelphia College of Pharmacy and Science）的药学学士学位和圣母大学（University of Notre Dame）的工商管理硕士学位。
- Scott Jackson,has more than thirty years of corporate leadership experience in the pharmaceutical and biotechnology industry and has held positions of increasing responsibility in sales, marketing and commercial development at Eli Lilly & Company, SmithKline Beecham plc, ImClone Systems Incorporated, Centocor Inc., a division of Johnson & Johnson, Eximias Pharmaceutical Corporation and YM BioSciences Inc. Mr. Jackson presently serves as chairman of the board of Mural Oncology plc, serves on the board of MacroGenics, Inc. and served on the board of GlycoMimetics, Inc. until February 2025. Mr. Jackson also serves on the board of directors at Philabundance, a non-profit organization that addresses food insecurity in the Philadelphia area. Mr. Jackson holds a B.S. in pharmacy from the Philadelphia College of Pharmacy and Science and an M.B.A. from the University of Notre Dame.
- Esther Rajavelu
-
Esther Rajavelu，于2022年1月至2023年4月担任Fulcrum Therapeutics, Inc.（“Fulcrum”）的首席财务官。在加入Fulcrum之前，Rajavelu女士在生物技术领域的职业生涯包括担任股票研究分析师、投资银行家和战略顾问。她于2020年7月至2021年12月担任瑞银证券（“瑞银”）高级股票研究分析师。在加入瑞银之前，Rajavelu女士曾于2018年6月至2020年7月在Oppenheimer & Co. Inc.（“Oppenheimer”）担任高级股票研究分析师。在加入奥本海默之前，Rajavelu女士于2014年6月至2018年6月期间担任德意志银行的股票研究分析师。在加入德意志银行之前，她曾于2011年至2014年在Ernst & Young Capital Advisors，LLC（“安永资本顾问”）担任负责生命科学并购和资本与债务咨询的副总裁。在加入安永资本顾问公司之前，她于2006年至2011年在美银美林的医疗保健投资银行集团工作，专注于生物技术和医疗器械领域的融资和战略交易。Rajavelu女士获得了宾夕法尼亚大学沃顿商学院的工商管理硕士学位和卫斯理大学的经济学和国际关系学士学位。
Esther Rajavelu,served as Chief Financial Officer of Fulcrum Therapeutics, Inc. ("Fulcrum") from January 2022 to April 2023. Prior to joining Fulcrum, Ms. Rajavelu's career in the biotechnology sector includes her time as an equities research analyst, investment banker, and strategy consultant. She served as a senior equities research analyst at UBS Securities ("UBS") from July 2020 to December 2021. Prior to joining UBS, Ms. Rajavelu served as a senior equities research analyst at Oppenheimer & Co. Inc. ("Oppenheimer") from June 2018 to July 2020. Prior to joining Oppenheimer, Ms. Rajavelu served as an equities research analyst at Deutsche Bank from June 2014 to June 2018. Prior to joining Deutsche Bank, she served as vice president, life sciences M&A and capital & debt advisory at Ernst & Young Capital Advisors, LLC ("EY Capital Advisors") from 2011 to 2014. Prior to joining EY Capital Advisors, she worked at Bank of America Merrill Lynch from 2006 to 2011 in the healthcare investment banking group where she focused on financing and strategic transactions in the biotechnology and medical devices sectors. Ms. Rajavelu received an M.B.A. from The Wharton School of the University of Pennsylvania and a B.A. in Economics and International Relations from Wesleyan University. - Esther Rajavelu，于2022年1月至2023年4月担任Fulcrum Therapeutics, Inc.（“Fulcrum”）的首席财务官。在加入Fulcrum之前，Rajavelu女士在生物技术领域的职业生涯包括担任股票研究分析师、投资银行家和战略顾问。她于2020年7月至2021年12月担任瑞银证券（“瑞银”）高级股票研究分析师。在加入瑞银之前，Rajavelu女士曾于2018年6月至2020年7月在Oppenheimer & Co. Inc.（“Oppenheimer”）担任高级股票研究分析师。在加入奥本海默之前，Rajavelu女士于2014年6月至2018年6月期间担任德意志银行的股票研究分析师。在加入德意志银行之前，她曾于2011年至2014年在Ernst & Young Capital Advisors，LLC（“安永资本顾问”）担任负责生命科学并购和资本与债务咨询的副总裁。在加入安永资本顾问公司之前，她于2006年至2011年在美银美林的医疗保健投资银行集团工作，专注于生物技术和医疗器械领域的融资和战略交易。Rajavelu女士获得了宾夕法尼亚大学沃顿商学院的工商管理硕士学位和卫斯理大学的经济学和国际关系学士学位。
- Esther Rajavelu,served as Chief Financial Officer of Fulcrum Therapeutics, Inc. ("Fulcrum") from January 2022 to April 2023. Prior to joining Fulcrum, Ms. Rajavelu's career in the biotechnology sector includes her time as an equities research analyst, investment banker, and strategy consultant. She served as a senior equities research analyst at UBS Securities ("UBS") from July 2020 to December 2021. Prior to joining UBS, Ms. Rajavelu served as a senior equities research analyst at Oppenheimer & Co. Inc. ("Oppenheimer") from June 2018 to July 2020. Prior to joining Oppenheimer, Ms. Rajavelu served as an equities research analyst at Deutsche Bank from June 2014 to June 2018. Prior to joining Deutsche Bank, she served as vice president, life sciences M&A and capital & debt advisory at Ernst & Young Capital Advisors, LLC ("EY Capital Advisors") from 2011 to 2014. Prior to joining EY Capital Advisors, she worked at Bank of America Merrill Lynch from 2006 to 2011 in the healthcare investment banking group where she focused on financing and strategic transactions in the biotechnology and medical devices sectors. Ms. Rajavelu received an M.B.A. from The Wharton School of the University of Pennsylvania and a B.A. in Economics and International Relations from Wesleyan University.
- Frank E. Thomas
-
Frank E. Thomas，在2011年8月加入Spero Therapeutics, Inc.，担任Spero Therapeutics, Inc.的执行副总裁、首席财务官和财务主管，目前担任执行副总裁兼首席运营官。从2011年11月至2012年5月，他还担任临时董事长和首席执行官。在加入Spero Therapeutics, Inc.之前，从2008年10月到2011年7月，他担任Molecular Biometrics商业阶段医疗诊断公司的高级副总裁、首席运营官和首席财务官。加入Molecular Biometrics之前，从2004年4月到2008年3月，他在Critical Therapeutics公共生物制药公司任职4年， 2006年6月，他被提升为总裁兼首席执行官，2006年12月，担任高级副总裁兼首席财务官。从2006年到2008年，他担任Critical Therapeutics的董事会主席。2004年之前，他担任Esperion Therapeutics生物制药公司的首席财务官和金融投资副董事长。自2007年起，他一直担任麻萨诸塞州生物技术委员会的董事会成员。他持有安娜堡密歇根大学的商业管理学士学位。
Frank E. Thomas,served as the President and Chief Operating Officer of AMAG Pharmaceuticals, Inc. ("AMAG"), a commercial-stage pharmaceutical company, which was a publicly traded company that was subsequently acquired by Covis Pharmaceuticals, Inc., from April 2015 to April 2017, as AMAG's Executive Vice President and Chief Operating Officer from May 2012 through April 2015 and as Executive Vice President, Chief Financial Officer and Treasurer from August 2011 through May 2012. Prior to AMAG, he served as Senior Vice President, Chief Operating Officer and Chief Financial Officer for Molecular Biometrics, Inc., a commercial-stage medical diagnostics company, from October 2008 to July 2011. Prior to Molecular Biometrics, Mr. Thomas spent four years at Critical Therapeutics, Inc., which was a publicly traded company that subsequently merged with Cornerstone Therapeutics Inc., from April 2004 to March 2008, where he was promoted to President in June 2006 and Chief Executive Officer in December 2006 from the position of Senior Vice President and Chief Financial Officer. He also served on the board of directors of Critical Therapeutics from 2006 to 2008. Prior to 2004, Mr. Thomas served as the Chief Financial Officer and Vice President of Finance and Investor Relations at Esperion Therapeutics, Inc., a public biopharmaceutical company. Mr. Thomas was a member of the board of directors of the Massachusetts Biotechnology Council from 2007 to 2015. Mr. Thomas currently serves as a member of the board of directors of Larimar Therapeutics Inc. Mr. Thomas holds a B.B.A. from the University of Michigan, Ann Arbor. - Frank E. Thomas，在2011年8月加入Spero Therapeutics, Inc.，担任Spero Therapeutics, Inc.的执行副总裁、首席财务官和财务主管，目前担任执行副总裁兼首席运营官。从2011年11月至2012年5月，他还担任临时董事长和首席执行官。在加入Spero Therapeutics, Inc.之前，从2008年10月到2011年7月，他担任Molecular Biometrics商业阶段医疗诊断公司的高级副总裁、首席运营官和首席财务官。加入Molecular Biometrics之前，从2004年4月到2008年3月，他在Critical Therapeutics公共生物制药公司任职4年， 2006年6月，他被提升为总裁兼首席执行官，2006年12月，担任高级副总裁兼首席财务官。从2006年到2008年，他担任Critical Therapeutics的董事会主席。2004年之前，他担任Esperion Therapeutics生物制药公司的首席财务官和金融投资副董事长。自2007年起，他一直担任麻萨诸塞州生物技术委员会的董事会成员。他持有安娜堡密歇根大学的商业管理学士学位。
- Frank E. Thomas,served as the President and Chief Operating Officer of AMAG Pharmaceuticals, Inc. ("AMAG"), a commercial-stage pharmaceutical company, which was a publicly traded company that was subsequently acquired by Covis Pharmaceuticals, Inc., from April 2015 to April 2017, as AMAG's Executive Vice President and Chief Operating Officer from May 2012 through April 2015 and as Executive Vice President, Chief Financial Officer and Treasurer from August 2011 through May 2012. Prior to AMAG, he served as Senior Vice President, Chief Operating Officer and Chief Financial Officer for Molecular Biometrics, Inc., a commercial-stage medical diagnostics company, from October 2008 to July 2011. Prior to Molecular Biometrics, Mr. Thomas spent four years at Critical Therapeutics, Inc., which was a publicly traded company that subsequently merged with Cornerstone Therapeutics Inc., from April 2004 to March 2008, where he was promoted to President in June 2006 and Chief Executive Officer in December 2006 from the position of Senior Vice President and Chief Financial Officer. He also served on the board of directors of Critical Therapeutics from 2006 to 2008. Prior to 2004, Mr. Thomas served as the Chief Financial Officer and Vice President of Finance and Investor Relations at Esperion Therapeutics, Inc., a public biopharmaceutical company. Mr. Thomas was a member of the board of directors of the Massachusetts Biotechnology Council from 2007 to 2015. Mr. Thomas currently serves as a member of the board of directors of Larimar Therapeutics Inc. Mr. Thomas holds a B.B.A. from the University of Michigan, Ann Arbor.
- Patrick Vink
-
Patrick Vink，2012年9月开始，他就是高级业务部的总经理和高级副总裁。在这之前，他是迈兰公司，（一家由他协调公司所有上市业务的上市制药公司）的医院业务全球主管和生物制品的全球主管和高级副总裁。2008年他加入迈兰，建立了瑞士的公司业务，这是一些全球功能的基础。在加入迈兰前，他在制药公司担任领导职位，包括山德士商业特效经营商业制药公司，诺华制药公司的分部的领导。诺华公司是一家上市全球制药公司。他是Biogen公司的欧洲中部和国际销售副总裁，他是赛诺菲圣德拉堡，（一家全球保健公司）的心血管和血栓形成的全球市场部的董事。
Patrick Vink,has served on Spero Therapeutics, Inc. Board of Directors since September 2015 and currently serves as Spero Therapeutics, Inc. Lead Director, a position he has held since August 2023. Dr. Vink has been an advisor to the pharmaceutical industry since 2015 and board member of several companies. Previously, Dr. Vink was employed at Cubist Pharmaceuticals, Inc ("Cubist"). Most recently, he served as Executive Vice-President and Chief Operating Officer, overseeing all worldwide commercial and technical operations as well as global alliance management and managing the company's profit and loss. He joined Cubist in 2012 as Senior Vice President and Head of all International Business Operations. In this role, he was responsible for the business activities in International markets outside USA. Prior to joining Cubist, Dr. Vink served as Senior Vice President, Global Head of Hospital Business and Global Head of Biologics for Mylan Inc. In this role, Dr. Vink managed the global hospital business of the company. He joined Mylan in 2008 and established a number of global functions for the company in Switzerland. Before joining Mylan, Dr. Vink held several leadership positions across the industry, including Head of Global Business Franchise Biopharmaceuticals for Novartis Sandoz; Vice President International Business for Biogen, Inc.; and Head of Worldwide Marketing, Cardiovascular and Thrombosis for Sanofi-Synthélabo SA. Dr. Vink served as a member of the Executive Committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA) between 2013 and 2015. Dr. Vink graduated as a medical doctor from the University of Leiden, Netherlands in 1988 and obtained his M.B.A. in 1992 from the University of Rochester. Dr. Vink serves on the boards of directors of Santhera Pharmaceuticals AG, Amryt Pharma PLC., and is Chairman of the board of directors of two privately held companies. - Patrick Vink，2012年9月开始，他就是高级业务部的总经理和高级副总裁。在这之前，他是迈兰公司，（一家由他协调公司所有上市业务的上市制药公司）的医院业务全球主管和生物制品的全球主管和高级副总裁。2008年他加入迈兰，建立了瑞士的公司业务，这是一些全球功能的基础。在加入迈兰前，他在制药公司担任领导职位，包括山德士商业特效经营商业制药公司，诺华制药公司的分部的领导。诺华公司是一家上市全球制药公司。他是Biogen公司的欧洲中部和国际销售副总裁，他是赛诺菲圣德拉堡，（一家全球保健公司）的心血管和血栓形成的全球市场部的董事。
- Patrick Vink,has served on Spero Therapeutics, Inc. Board of Directors since September 2015 and currently serves as Spero Therapeutics, Inc. Lead Director, a position he has held since August 2023. Dr. Vink has been an advisor to the pharmaceutical industry since 2015 and board member of several companies. Previously, Dr. Vink was employed at Cubist Pharmaceuticals, Inc ("Cubist"). Most recently, he served as Executive Vice-President and Chief Operating Officer, overseeing all worldwide commercial and technical operations as well as global alliance management and managing the company's profit and loss. He joined Cubist in 2012 as Senior Vice President and Head of all International Business Operations. In this role, he was responsible for the business activities in International markets outside USA. Prior to joining Cubist, Dr. Vink served as Senior Vice President, Global Head of Hospital Business and Global Head of Biologics for Mylan Inc. In this role, Dr. Vink managed the global hospital business of the company. He joined Mylan in 2008 and established a number of global functions for the company in Switzerland. Before joining Mylan, Dr. Vink held several leadership positions across the industry, including Head of Global Business Franchise Biopharmaceuticals for Novartis Sandoz; Vice President International Business for Biogen, Inc.; and Head of Worldwide Marketing, Cardiovascular and Thrombosis for Sanofi-Synthélabo SA. Dr. Vink served as a member of the Executive Committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA) between 2013 and 2015. Dr. Vink graduated as a medical doctor from the University of Leiden, Netherlands in 1988 and obtained his M.B.A. in 1992 from the University of Rochester. Dr. Vink serves on the boards of directors of Santhera Pharmaceuticals AG, Amryt Pharma PLC., and is Chairman of the board of directors of two privately held companies.
- Cynthia Smith
-
Cynthia Smith是理学硕士和工商管理硕士，自2013年6月以来担任Spero Therapeutics, Inc.的首席商务官。从2008年10月到2013年3月她在Affymax Inc.（关注新肾疗法的开发和商业化的生物技术公司）工作，最近是市场准入和商业发展（Market Access and Commercial Development）的副总裁。从2000年7月到2008年10月她在Merck and Co., Inc.工作，在那里她担任各种管理市场、公司战略和公共事务的领导职位，最近担任医疗体系和医疗战略（Healthcare System and Medicare Strategy）的执行董事。从1995年6月到2000年7月她在克林顿政府下的白宫行政管理和预算局工作。她从北卡罗莱纳大学教堂山分校获得学士学位，从罗格斯大学伊格尔顿研究所获得公共政策硕士学位，从宾夕法尼亚大学沃顿商学院获得工商管理硕士学位。
Cynthia Smith,served as Chief Commercial Officer of ZS Pharma, Inc., from June 2013 to December 2016. In December 2015, ZS Pharma, Inc. was acquired and became a subsidiary of AstraZeneca. Prior to joining ZS Pharma, Inc., from October 2008 to March 2013, Ms. Smith served as Vice President, Market Access & Commercial Development at Affymax, Inc., a biotechnology company focused on the development and commercialization of novel renal therapies, including a new anemia drug for chronic kidney disease patients. Prior to Affymax, from 2000 to 2008, she held various senior leadership positions in market access, corporate strategy, government relations and external affairs at Merck & Co. Before joining the pharmaceutical industry, Ms. Smith served in the White House Office of Management and Budget (OMB) in the Clinton Administration. Ms. Smith serves on the board of directors of Agios Pharmaceuticals, Akebia Therapeutics, Protara Therapeutics, Inc. and Tvardi Therapeutics, Inc. Ms. Smith earned an M.B.A. from the Wharton School of the University of Pennsylvania, an M.S. in public policy from the Eagleton Institute of Politics at Rutgers University, and a B.A. from the University of North Carolina at Chapel Hill. - Cynthia Smith是理学硕士和工商管理硕士，自2013年6月以来担任Spero Therapeutics, Inc.的首席商务官。从2008年10月到2013年3月她在Affymax Inc.（关注新肾疗法的开发和商业化的生物技术公司）工作，最近是市场准入和商业发展（Market Access and Commercial Development）的副总裁。从2000年7月到2008年10月她在Merck and Co., Inc.工作，在那里她担任各种管理市场、公司战略和公共事务的领导职位，最近担任医疗体系和医疗战略（Healthcare System and Medicare Strategy）的执行董事。从1995年6月到2000年7月她在克林顿政府下的白宫行政管理和预算局工作。她从北卡罗莱纳大学教堂山分校获得学士学位，从罗格斯大学伊格尔顿研究所获得公共政策硕士学位，从宾夕法尼亚大学沃顿商学院获得工商管理硕士学位。
- Cynthia Smith,served as Chief Commercial Officer of ZS Pharma, Inc., from June 2013 to December 2016. In December 2015, ZS Pharma, Inc. was acquired and became a subsidiary of AstraZeneca. Prior to joining ZS Pharma, Inc., from October 2008 to March 2013, Ms. Smith served as Vice President, Market Access & Commercial Development at Affymax, Inc., a biotechnology company focused on the development and commercialization of novel renal therapies, including a new anemia drug for chronic kidney disease patients. Prior to Affymax, from 2000 to 2008, she held various senior leadership positions in market access, corporate strategy, government relations and external affairs at Merck & Co. Before joining the pharmaceutical industry, Ms. Smith served in the White House Office of Management and Budget (OMB) in the Clinton Administration. Ms. Smith serves on the board of directors of Agios Pharmaceuticals, Akebia Therapeutics, Protara Therapeutics, Inc. and Tvardi Therapeutics, Inc. Ms. Smith earned an M.B.A. from the Wharton School of the University of Pennsylvania, an M.S. in public policy from the Eagleton Institute of Politics at Rutgers University, and a B.A. from the University of North Carolina at Chapel Hill.
高管简历
中英对照 | 中文 | 英文- Timothy Keutzer
Timothy Keutzer自2019年6月起担任我们的首席开发官。他在制药行业拥有超过20年的经验，涉及多个功能和治疗领域。加入Spero之前，Keutzer曾在Cubist Pharmaceuticals担任多个职位，包括2014年5月至2015年7月担任项目和投资组合管理Vice President。在Cubist，Keutzer先生是头孢托洛赞/他唑巴坦的项目负责人，该项目从第1阶段快速发展到第3阶段，并于2014年12月获得FDA批准。在担任该职位之前，他还领导了Cubist&8217；s的几个未经许可的开发项目，并领导了Cubicin的商业供应链。Cubist之前的经验跨越多个药物类别，包括Genetics Institute的临床前PK/PD和临床运营，以及Wyeth的全球战略营销和项目管理。Tim在Contract Toxicology Labs开始他的职业生涯。Keutzer先生在肯塔基大学获得学士学位。
Timothy Keutzer,served in various roles at Cubist Pharmaceuticals, including Vice President of Program and Portfolio Management from May 2014 to July 2015. At Cubist Mr. Keutzer was the program leader for ceftolozane/tazobactam, which progressed rapidly from Phase 1 to Phase 3, and was approved in the FDA in December of 2014. Prior to that role, he also led several of Cubist's in-licensed development programs and also led the commercial supply chain for Cubicin. His experience before Cubist spans multiple drug classes and includes preclinical PK/PD and clinical operations at Genetics Institute, as well as global strategic marketing and program management at Wyeth. Tim began his career in contract toxicology labs. Mr. Keutzer earned his bachelor's degree from the University of Kentucky.- Timothy Keutzer自2019年6月起担任我们的首席开发官。他在制药行业拥有超过20年的经验，涉及多个功能和治疗领域。加入Spero之前，Keutzer曾在Cubist Pharmaceuticals担任多个职位，包括2014年5月至2015年7月担任项目和投资组合管理Vice President。在Cubist，Keutzer先生是头孢托洛赞/他唑巴坦的项目负责人，该项目从第1阶段快速发展到第3阶段，并于2014年12月获得FDA批准。在担任该职位之前，他还领导了Cubist&8217；s的几个未经许可的开发项目，并领导了Cubicin的商业供应链。Cubist之前的经验跨越多个药物类别，包括Genetics Institute的临床前PK/PD和临床运营，以及Wyeth的全球战略营销和项目管理。Tim在Contract Toxicology Labs开始他的职业生涯。Keutzer先生在肯塔基大学获得学士学位。
- Timothy Keutzer,served in various roles at Cubist Pharmaceuticals, including Vice President of Program and Portfolio Management from May 2014 to July 2015. At Cubist Mr. Keutzer was the program leader for ceftolozane/tazobactam, which progressed rapidly from Phase 1 to Phase 3, and was approved in the FDA in December of 2014. Prior to that role, he also led several of Cubist's in-licensed development programs and also led the commercial supply chain for Cubicin. His experience before Cubist spans multiple drug classes and includes preclinical PK/PD and clinical operations at Genetics Institute, as well as global strategic marketing and program management at Wyeth. Tim began his career in contract toxicology labs. Mr. Keutzer earned his bachelor's degree from the University of Kentucky.
- Esther Rajavelu
Esther Rajavelu，于2022年1月至2023年4月担任Fulcrum Therapeutics, Inc.（“Fulcrum”）的首席财务官。在加入Fulcrum之前，Rajavelu女士在生物技术领域的职业生涯包括担任股票研究分析师、投资银行家和战略顾问。她于2020年7月至2021年12月担任瑞银证券（“瑞银”）高级股票研究分析师。在加入瑞银之前，Rajavelu女士曾于2018年6月至2020年7月在Oppenheimer & Co. Inc.（“Oppenheimer”）担任高级股票研究分析师。在加入奥本海默之前，Rajavelu女士于2014年6月至2018年6月期间担任德意志银行的股票研究分析师。在加入德意志银行之前，她曾于2011年至2014年在Ernst & Young Capital Advisors，LLC（“安永资本顾问”）担任负责生命科学并购和资本与债务咨询的副总裁。在加入安永资本顾问公司之前，她于2006年至2011年在美银美林的医疗保健投资银行集团工作，专注于生物技术和医疗器械领域的融资和战略交易。Rajavelu女士获得了宾夕法尼亚大学沃顿商学院的工商管理硕士学位和卫斯理大学的经济学和国际关系学士学位。
Esther Rajavelu,served as Chief Financial Officer of Fulcrum Therapeutics, Inc. ("Fulcrum") from January 2022 to April 2023. Prior to joining Fulcrum, Ms. Rajavelu's career in the biotechnology sector includes her time as an equities research analyst, investment banker, and strategy consultant. She served as a senior equities research analyst at UBS Securities ("UBS") from July 2020 to December 2021. Prior to joining UBS, Ms. Rajavelu served as a senior equities research analyst at Oppenheimer & Co. Inc. ("Oppenheimer") from June 2018 to July 2020. Prior to joining Oppenheimer, Ms. Rajavelu served as an equities research analyst at Deutsche Bank from June 2014 to June 2018. Prior to joining Deutsche Bank, she served as vice president, life sciences M&A and capital & debt advisory at Ernst & Young Capital Advisors, LLC ("EY Capital Advisors") from 2011 to 2014. Prior to joining EY Capital Advisors, she worked at Bank of America Merrill Lynch from 2006 to 2011 in the healthcare investment banking group where she focused on financing and strategic transactions in the biotechnology and medical devices sectors. Ms. Rajavelu received an M.B.A. from The Wharton School of the University of Pennsylvania and a B.A. in Economics and International Relations from Wesleyan University.- Esther Rajavelu，于2022年1月至2023年4月担任Fulcrum Therapeutics, Inc.（“Fulcrum”）的首席财务官。在加入Fulcrum之前，Rajavelu女士在生物技术领域的职业生涯包括担任股票研究分析师、投资银行家和战略顾问。她于2020年7月至2021年12月担任瑞银证券（“瑞银”）高级股票研究分析师。在加入瑞银之前，Rajavelu女士曾于2018年6月至2020年7月在Oppenheimer & Co. Inc.（“Oppenheimer”）担任高级股票研究分析师。在加入奥本海默之前，Rajavelu女士于2014年6月至2018年6月期间担任德意志银行的股票研究分析师。在加入德意志银行之前，她曾于2011年至2014年在Ernst & Young Capital Advisors，LLC（“安永资本顾问”）担任负责生命科学并购和资本与债务咨询的副总裁。在加入安永资本顾问公司之前，她于2006年至2011年在美银美林的医疗保健投资银行集团工作，专注于生物技术和医疗器械领域的融资和战略交易。Rajavelu女士获得了宾夕法尼亚大学沃顿商学院的工商管理硕士学位和卫斯理大学的经济学和国际关系学士学位。
- Esther Rajavelu,served as Chief Financial Officer of Fulcrum Therapeutics, Inc. ("Fulcrum") from January 2022 to April 2023. Prior to joining Fulcrum, Ms. Rajavelu's career in the biotechnology sector includes her time as an equities research analyst, investment banker, and strategy consultant. She served as a senior equities research analyst at UBS Securities ("UBS") from July 2020 to December 2021. Prior to joining UBS, Ms. Rajavelu served as a senior equities research analyst at Oppenheimer & Co. Inc. ("Oppenheimer") from June 2018 to July 2020. Prior to joining Oppenheimer, Ms. Rajavelu served as an equities research analyst at Deutsche Bank from June 2014 to June 2018. Prior to joining Deutsche Bank, she served as vice president, life sciences M&A and capital & debt advisory at Ernst & Young Capital Advisors, LLC ("EY Capital Advisors") from 2011 to 2014. Prior to joining EY Capital Advisors, she worked at Bank of America Merrill Lynch from 2006 to 2011 in the healthcare investment banking group where she focused on financing and strategic transactions in the biotechnology and medical devices sectors. Ms. Rajavelu received an M.B.A. from The Wharton School of the University of Pennsylvania and a B.A. in Economics and International Relations from Wesleyan University.